WorldPingSTAT
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.
Brief by WorldPing · Original reporting by STAT
WorldPing